Skip to main content

Advertisement

SpringerLink
Log in

Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Tryptase acting at protease-activated receptor 2 (PAR2) contributes to the pathogenesis of Inflammatory bowel diseases (IBDs). DNA methylation has been shown to be an important mechanism in gene silencing. We attempted to clarify the relationship between the promoter methylation of PAR2 and ulcerative colitis (UC). 84 UC patients enrolled in the study. UC patients were classified by disease behavior, severity and extent of disease. For rectal inflammatory mucosal specimens from all the patients, and normal terminal ileum from 23 patients, promoter methylation of PAR2 gene was quantified by digital densitographic analysis following to methylation-specific polymerase chain reaction (MSP). The mean methylation levels of the PAR2 gene in all 84 subjects was 38.4 ± 19.6%. Although mean methylation levels in rectal inflammatory mucosa, and paired normal terminal ileum did not vary, methylation levels of PAR2 gene was significantly higher in total colitis than rectal colitis (total colitis vs. rectal colitis; 42.9 ± 19.6% vs. 34.5 ± 18.9%, P = 0.046). The higher methylation levels were also associated with Steroid-dependent (P = 0.002) and refractory (P = 0.007) UC. Our data suggest that PAR2 methylation status in rectal mucosa correlates with more severe disease phenotypes of UC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG (2001) Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 36:174–179

    Article  PubMed  CAS  Google Scholar 

  2. Cenac N, Coelho AM, Nauyen C, Compton S, Patricia AG, Wallace K (2002) Induction of intestinal inflammation in mouse by activation of protease-activated receptor-2. Am J Pathol 161:1903–1915

    PubMed  CAS  Google Scholar 

  3. Tremaine WJ, Brezezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J (2002) Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Parmacol Ther 16:407–413

    Article  CAS  Google Scholar 

  4. Yamada T, Marshall S, Specian RD, Grisham MB (1992) A comparative analysis of two models of colitis in rats. Gastroenterology 102:1524–1534

    PubMed  CAS  Google Scholar 

  5. Dery O, Corvera CU, Steinhoff M, Bunnett NW (1998) Proteinaseactivated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274:C1429–C1452

    PubMed  CAS  Google Scholar 

  6. Schmildlin F, Bunnett NW (2001) Protease-activated receptors: how proteases signal to cells. Curr Opin Pharmacol 1:575–582

    Article  Google Scholar 

  7. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF (1997) Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272:4043–4049

    Article  PubMed  CAS  Google Scholar 

  8. Molino M, Woolkalis MJ, Reavey-Cantwell J, Praticó D, Andrade-Gordon P, Barnathan ES, Brass LF, Endothelial cell thrombin receptors and PAR-2 (1997) Two protease-activated receptors located in a single cellular environment. J Biol Chem 272:11133–11141

    Article  PubMed  CAS  Google Scholar 

  9. Howells GL, Macey MG, Chinni C, Hou L, Fox MT, Harriott P, Stone SR (1997) Proteinase-activated receptor-2: expression by human neutrophils. J Cell Sci 110:881–887

    PubMed  CAS  Google Scholar 

  10. Bertog M, Letz B, Kong W, Steinhoff M, Higgins MA, Bielfeld-Ackermann A, Frömter E, Bunnett NW, Korbmacher C (1999) Basolateral proteinase-activated receptor (PAR-2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells. J Physiol 521:3–17

    Article  PubMed  CAS  Google Scholar 

  11. Cenac N, Chin AC, Garcia-Villar R, Salvador-Cartier C, Ferrier L, Vergnolle N, Buret AG, Fioramonti J, Bueno L (2004) PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. J Physiol 558:913–925

    Article  PubMed  CAS  Google Scholar 

  12. Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, Yeom JJ, Kim TH, Nah YH, Lee YM (2003) Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 9:224–229

    Article  PubMed  Google Scholar 

  13. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG Island links ageing and neoplasia in human colon. Nat Genet 4:536–540

    Article  Google Scholar 

  14. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 23:5489–5494

    Google Scholar 

  15. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, Selaru FM, Kimos MC, Hytiroglou P, Young J, Leggett B, Gazdar AF, Toyooka S, Abraham JM, Meltzer SJ (2002) Hypermethylation of the p14 (ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62:1148–1151

    PubMed  CAS  Google Scholar 

  16. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61:3573–3577

    PubMed  CAS  Google Scholar 

  17. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett’s esophagus. Gastroenterology 122:1113–1121

    Article  PubMed  CAS  Google Scholar 

  18. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ (2001) p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res 61:8284–8289

    PubMed  CAS  Google Scholar 

  19. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K (2001) Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48:372–377

    Article  PubMed  CAS  Google Scholar 

  20. Podolsky DK (1991) Inflammatory bowel disease 2. N Engl J Med 325:928–937

    PubMed  CAS  Google Scholar 

  21. Langholz E, Munkholm P, Davidsen M, Binder V (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107:3–11

    PubMed  CAS  Google Scholar 

  22. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Takagi T, Hasegawa S, Wang FY, Hirata I, Nakano H (2007) Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. J Gastroenterol Hepatol 22:943–948

    Article  PubMed  CAS  Google Scholar 

  23. Tahara T, Arisawa T, Shibata T, Wang FY, Nakamura M, Sakata M, Nagasaka M, Takagi T, Kamiya Y, Fujita H, Nakamura M, Hasegawa S, Iwata M, Takahama K, Watanabe M, Hirata I, Nakano H (2007) Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 75:54–61

    Article  PubMed  CAS  Google Scholar 

  24. Tominaga K, Fujii S, Mukawa K, IchiKawa K, Tomita S, Imai Y, Kanke K, Ono Y, ImuTerano A, Hiraishi H, Fujimori T (2005) Prediction of colorectal neooplasia by quantitative methylation analysis of estrogen receptor gene in non-neoplastis epithelium from patients with ulcerative colitis. Clin Cancer Res 11:8880–8885

    Article  PubMed  CAS  Google Scholar 

  25. Wang FY, Arisawa T, Tahara T, Takahama K, Watanabe M, Hirata I, Nakano H (2008) Aberrant DNA methylation in ulcerative colitis without neoplasia, Hepato-Gestroenterol, (in press)

  26. Velicescu M, Weisenberger DJ, Gonzales FA, Tsai YC, Nguyen CT, Jones PA (2002) Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 62:2378–2384

    PubMed  CAS  Google Scholar 

  27. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ (2002) Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21:1048–1061

    Article  PubMed  CAS  Google Scholar 

  28. De Smet C, Loriot A, Boon T (2004) Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24:4781–4790

    Article  PubMed  Google Scholar 

  29. Ushijima T, Okochi-Takada E (2005) Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96:206–211

    Article  PubMed  CAS  Google Scholar 

  30. Vergnolle N, Hollenberg MD, Sharkey K, Wallace JL (1999) Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR-2)-activating peptides in the rat paw. Br J Pharmacol 127:1083–1090

    Article  PubMed  CAS  Google Scholar 

  31. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD (2001) Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146–152

    Article  PubMed  CAS  Google Scholar 

  32. Steinhoff M, Vergnolle N, Young S, Tognetto M, Amadesi S, Ennes H, Trevisani M, Hollenberg MD, Wallace JL, Caughey G, Mitchell S, Williams L, Geppetti P, Mayer E, Bunnett N (2000) Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6:151–158

    Article  PubMed  CAS  Google Scholar 

  33. Damiano B, Cheung W, Santulli R, Fung-Leung P, Ngo K, Ye R, Darrow A, Derian C, De Garavilla L, Andrade-Gordon P (1999) Cardiovascular responses mediated by proteinase-activated receptor 2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 288:671–678

    PubMed  CAS  Google Scholar 

  34. Hwa J, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, Sybertz E (1996) Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res 78:581–588

    PubMed  CAS  Google Scholar 

  35. Vergnolle N (1999) Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol 163:5064–5069

    PubMed  CAS  Google Scholar 

  36. Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN (2001) Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res 21:231–240

    Article  PubMed  CAS  Google Scholar 

  37. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD (1999) A protective role for protease-activated receptors in the airways. Nature 398:156–160

    Article  PubMed  CAS  Google Scholar 

  38. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G (2001) Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci USA 98:13936–13941

    Article  PubMed  CAS  Google Scholar 

  39. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G (2000) Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci USA 97:3678–3683

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan

    Tomomitsu Tahara, Tomoyuki Shibata, Masakatsu Nakamura, Hiromi Yamashita, Daisuke Yoshioka, Masaaki Okubo, Naoko Maruyama, Toshiaki Kamano, Yoshio Kamiya, Hiroshi Fujita, Yoshihito Nakagawa, Mitsuo Nagasaka, Masami Iwata, Kazuya Takahama, Makoto Watanabe, Ichiro Hirata & Tomiyasu Arisawa

  2. Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan

    Hiroshi Nakano

  3. Kanazawa Medical University, 1-1 Daigaku, Uchinadamachi, Ishikawa, 920-0293, Japan

    Tomiyasu Arisawa

Authors
  1. Tomomitsu Tahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masakatsu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiromi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaaki Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiaki Kamano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshio Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroshi Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshihito Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mitsuo Nagasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Masami Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kazuya Takahama
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Makoto Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroshi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ichiro Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Tomiyasu Arisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomomitsu Tahara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tahara, T., Shibata, T., Nakamura, M. et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med 9, 125–130 (2009). https://doi.org/10.1007/s10238-008-0025-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-008-0025-x

Keywords

Search

Navigation